Harmony Biosciences Holdings Inc Ordinary Shares HRMY
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
HARMONY BIOSCIENCES TO HOST FIRST INVESTOR DAY ON OCTOBER 1, 2024
-
HARMONY BIOSCIENCES TO PARTICIPATE IN UPCOMING INVESTOR CONFERENCES
-
HARMONY BIOSCIENCES TO REPORT SECOND QUARTER 2024 FINANCIAL RESULTS ON AUGUST 6, 2024
-
Harmony Biosciences Gets FDA Orphan Designation for Pitolisant in Prader-Willi Syndrome
-
Harmony Biosciences Stock Up as FDA Rejects to Reevaluate Narcolepsy Treatment Patent
Trading Information
- Previous Close Price
- $39.79
- Day Range
- $39.02–40.10
- 52-Week Range
- $18.61–40.10
- Bid/Ask
- $39.13 / $62.97
- Market Cap
- $2.22 Bil
- Volume/Avg
- 487,735 / 400,716
Key Statistics
- Price/Earnings (Normalized)
- 10.88
- Price/Sales
- 3.56
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- 4.42%
Company Profile
Harmony Biosciences Holdings Inc is a commercial-stage pharmaceutical company focused on developing and commercializing therapies for patients living with rare neurological diseases who have unmet medical needs. The company's product WAKIX (pitolisant), is a molecule with a novel mechanism of action specifically designed to increase histamine signaling in the brain by binding to H3 receptors and used for the treatment of cataplexy in adult patients with narcolepsy.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Growth
- Total Number of Employees
- 246
Comparables
Valuation
|
Metric
|
HRMY
|
FULC
|
EWTX
|
|---|---|---|---|
Price/Earnings (Normalized) | 10.88 | — | — |
Price/Book Value | 4.20 | 0.91 | 4.77 |
Price/Sales | 3.56 | 3.08 | — |
Price/Cash Flow | 11.11 | — | — |
Price/Earnings
HRMY
FULC
EWTX
Financial Strength
|
Metric
|
HRMY
|
FULC
|
EWTX
|
|---|---|---|---|
Quick Ratio | 2.93 | 21.84 | 29.79 |
Current Ratio | 3.13 | 22.07 | 30.24 |
Interest Coverage | 6.17 | — | — |
Quick Ratio
HRMY
FULC
EWTX
Profitability
|
Metric
|
HRMY
|
FULC
|
EWTX
|
|---|---|---|---|
Return on Assets (Normalized) | 26.26% | −1.76% | −23.23% |
Return on Equity (Normalized) | 42.80% | −1.91% | −24.43% |
Return on Invested Capital (Normalized) | 31.24% | −1.83% | −29.19% |
Return on Assets
HRMY
FULC
EWTX
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Novo Nordisk AS ADR
NVO
| Gsjdvptvjp | Mskp | $554.5 Bil | |||
| Vertex Pharmaceuticals Inc
VRTX
| Fqjwtyhpk | Zqczsk | $119.5 Bil | |||
| Regeneron Pharmaceuticals Inc
REGN
| Lkqmcrv | Bxtkvc | $114.6 Bil | |||
| Alnylam Pharmaceuticals Inc
ALNY
| Mpdwhfj | Gqtvvc | $35.2 Bil | |||
| argenx SE ADR
ARGX
| Tmrpjzyz | Cxk | $31.7 Bil | |||
| BioNTech SE ADR
BNTX
| Djgsxgdtc | Nfdf | $28.0 Bil | |||
| Moderna Inc
MRNA
| Bzqvxnyv | Lww | $24.6 Bil | |||
| United Therapeutics Corp
UTHR
| Ymrpktgsn | Kfxb | $15.9 Bil | |||
| Biomarin Pharmaceutical Inc
BMRN
| Nrfwgvw | Fxgvnm | $13.4 Bil | |||
| Royalty Pharma PLC Class A
RPRX
| Tzfbkgwpbn | Lsjpycc | $12.6 Bil |
United States